CHINA Law and Practice Contributed by: Catherine Chen and Shaun Gao, Zhong Lun Law Firm
Innovation ecosystem development Key pilot regions including Beijing, Shanghai, Guangdong and Hainan Free Trade Zones pro - vide comprehensive innovation ecosystems through systematic policy experimentation and gradual regulatory liberalisation. These con - trolled innovation corridors enable measured testing of regulatory reforms while maintaining strategic oversight through sophisticated moni - toring protocols and integrated compliance sys - tems. The framework demonstrates increasing sophistication in balancing innovation promo - tion with regulatory control through enhanced verification mechanisms and strategic alignment protocols. In a landmark policy shift for 2024, China sig - nificantly opened its gene therapy sector to for - eign investment, marking a strategic departure from its traditionally prohibited stance. Through a carefully structured pilot programme in desig - nated free trade zones, foreign enterprises can now invest in and develop technologies across key areas including human stem cell research, gene therapy, genetic diagnosis and cell therapy applications. This policy change not only dem - onstrates China’s commitment to advancing its biotechnology sector but also creates unprec - edented opportunities for international collabo - ration and knowledge transfer.
While maintaining necessary regulatory over - sight and compliance requirements, this opening is expected to accelerate China’s development in advanced medical treatments by attract - ing substantial foreign expertise and capital. The move reflects China’s broader strategy of strengthening its position in the global biotech - nology landscape while ensuring controlled and regulated market access for foreign participants in this sensitive healthcare sector.
131 CHAMBERS.COM
Powered by FlippingBook